Fresenius Medical Care AG & Co. KGaA

Investor Presentation • Jun 4, 2019

JEFFERIES HEALTHCARE CONFERENCE

JUNE 4-5, 2019

© Copyright

Safe harbor statement: This presentation includes certain forward -looking statements within the meaning of Section 27A of the U.S. Securities Act of 1933, as amended, and Section 21E of the U.S. Securities Act of 1934, as amended. Forward -looking statements are inherently subject to risks and uncertainties, many of which cannot be predicted with accuracy or might not even be anticipated. The Company has based these forward -looking statements on current estimates and assumptions which we believe are reasonable and which are made to the best of our knowledge. Actual results could differ materially from those included in the forward -looking statements due to various risk factors and uncertainties, including changes in business, economic or competitive conditions, changes in reimbursement, regulatory compliance issues, regulatory reforms, foreign exchange rate fluctuations, uncertainties in litigation or investigative proceedings, cyber security issues and the availability of financing. Given these uncertainties, readers should not put undue reliance on any forward -looking statements. These and other risks and uncertainties are discussed in detail in Fresenius Medical Care AG & Co. KGaA's (FMC AG & Co. KGaA) Annual Report on Form 20 -F under the heading "Forward -Looking Statements" and under the headings in that report referred to therein, and in FMC AG & Co. KGaA's other reports filed with the Securities and Exchange Commission (SEC) and the Frankfurt Stock Exchange (Frankfurter Wertpapierbörse).

Forward -looking statements represent estimates and assumptions only as of the date that they were made. The information contained in this presentation is subject to change without notice and the company does not undertake any duty to update the forward -looking statements, and the estimates and assumptions associated with them, except to the extent required by applicable law and regulations.

If not mentioned differently the term net income after minorities refers to the net income attributable to the shareholders of Fresenius Medical Care AG Co. KGaA. The term EMEA refers to the region Europe, Middle East and Africa. Amounts are in Euro if not mentioned otherwise.

2018: GROWTH CONTINUED

2018: €16.5BN REVENUE

Segment revenue FY 2018, number of patients and clinics as of YE 2018, yoy change │ 1 Including gain from divesture of Care Coordination activities

© │ June 2019

ORGANIC GROWTH DRIVERS

STRATEGY – CORE COMPETENCIES

GLOBAL MARKET LEADER IN DIALYSIS

• Innovate for enhancing patient care
• Market leading high quality products

• Solution selling

• Standardized medical procedures

• Enable best treatment outcomes

• Capture growth in developing markets

• Coordinating patients efficiently

• Data analytics & predictive modelling
• Develop & enhance value based care

DELIVERING ON OUR HOME STRATEGY

CAPTURE GROWTH IN DEVELOPING ECONOMIES

DEVELOPING ECONOMIES – EXAMPLE CHINA

▪ Early mover in developing economies with products first

• Leverage experience from the products business into the service business – e.g. advancing in the Chinese market with own dialysis clinics and renal hospitals
• Investing in manufacturing capacities in the growing and upcoming markets
• Expand Care Coordination outside North America
• Transfer know-how into new markets

Source: WORLD BANK

GLOBAL EFFICIENCY PROGRAM II

SUSTAINED SAVINGS 2018 - 2020

2018 AHEAD OF SCHEDULE

• Projects already positively contributed in the first year of the program
• 15% sustained savings generated in 2018 instead of originally targeted 10%

DIVIDEND INCREASE AND SHARE BUYBACK PROPOSED

DIVIDEND PER SHARE IN EURO

DIVIDEND PROPOSAL 2018

• 22nd consecutive dividend increase proposed
• Dividend proposal reflects investments in future growth
• We remain committed to our ambitious goal for the dividend development to be closely aligned with our growth in earnings per share, while maintaining dividend continuity.

SHARE BUYBACK

• Volume: up to EUR 1bn
• Time horizon: 2019-2020

1 Proposed dividend for approval at the AGM on May 16, 2019

2019 WILL BE AN INVESTMENT YEAR

FOCUS ON

• Resolving identified operational issues
• Invest around €100 million in 2019 cost optimization program
  • Further steps to improve cost base
  • Accretive to net income already in 2020
  • Additional efforts to GEP II
• GEP II with increasing contribution
• Share buyback: create additional shareholder return
• Capturing growth in developing economies
• Investing in growth of U.S. home treatments
• Integration of NxStage and realizing synergies

OPPORTUNITIES

• Higher contributions from GEP II
• Faster recovery of commercial volumes
• Higher contribution from expansion in developing economies

RISKS

• Lower than expected contribution from de novo clinics and acquisitions
• Legislative activities
• Unforeseen regulatory changes

Q1 2019: UPDATE

NxStage acquisition successfully closed and integration started

Underlying business development as expected

Earnings supported by agreements that materialized earlier than planned

Cost optimization program initiated

Non-prosecution agreement concluded with U.S. government

Outlook 2019 and 2020 confirmed

Q1 2019: SOLID START TO THE YEAR¹

	Q1 2019 € million	Q1 2018 € million	Growth in %	Growth in %cc
Revenue	4,133	3,976	4	(1)
Revenue adjusted	4,125	3,725	11	6
Operating income (EBIT)	537	497	8	3
EBIT adjusted	551	506	9	4
Net income	271	279	(3)	(6)
Net income adjusted	318	296	8	3

• Tailwind from FX effects
• Revenue adjusted growth in line with outlook
• Growth of net income adjusted ahead of expectations due to timing effects

1 For a detailed reconciliation please refer to chart 27

Q1 2019: ORGANIC GROWTH IN ALL REGIONS

NORTH AMERICA	€ million
Revenue	2,887	(4)%cc
Organic growth	+6%
EMEA	€ million
Revenue	653	+4%cc

Revenue	653	+4%cc
Organic growth		+4%

ASIA-PACIFIC	€ million
Revenue	428	+6%cc
Organic growth		+6%

LATIN AMERICA	€ million
Revenue	161	+14%cc
Organic growth		+13%

1 Organic growth

• Organic growth trend continued in all markets
• North America negatively impacted by the divestitures of Care Coordination activities
• Growth in Asia-Pacific and Latin America remains on a high level

Q1 2019 SERVICES: SOLID ORGANIC GROWTH CONTINUED

	Q1 2019 € million	Q1 2018 € million	Growth in %	Growth in %cc	Organic growth in %	Same market growth in %cc
Total	3,317	3,209	3	(2)	6	3
North America	2,680	2,590	3	(4)	6	3
of which Care Coordination	308	515	(40)	(45)	7	n.a.
EMEA	324	314	3	5	5	4
Asia-Pacific	199	184	8	4	5	7
of which Care Coordination	52	46	14	12	5	n.a.
Latin America	114	121	(5)	20	17	1

1 Organic growth

▪ North America growth negatively impacted by Care Coordination divestitures

▪ EMEA

positive development due to organic growth and acquisitions

▪ Asia-Pacific growth driven by same market treatment growth and acquisitions

Q1 2019 PRODUCTS: SOLID ORGANIC GROWTH IN ALL REGIONS

	Q1 2019 € million	Q1 2018 € million	Growth in %	Growth in %cc	Organic growth in %
Total Health Care Products	816	767	6	4	5
Dialysis Products	797	747	7	5	5
North America	2071	184	12	4	5
EMEA	310	302	3	3	4
Asia-Pacific	229	208	10	8	8
Latin America	47	49	(5)	1	1
Non-Dialysis Products	19	20	(3)	(3)	(3)

PRODUCT REVENUE DRIVEN BY

▪ EMEA machines, dialyzers, hemodialysis solutions and concentrates

• Asia-Pacific dialyzers, machines, hemodialysis solutions and concentrates
• North America stable development

1 Includes a positive contribution of €29 million from the NxStage acquisition and a negative effect of €22 million from IFRS 16 implementation │2 Organic growth

Q1 2019: CASH FLOW, NET LEVERAGE RATIO & CURRENT RATINGS

	Q1 2019 € million	Q1 2018 € million
Operating cash flow	76	(45)
in % of revenue	1.8	(1.1)
Capital expenditures, net	(199)	(218)
Free cash flow	(123)	(263)
Free cash flow, after net acquisitions and investments, incl. net investments in securities	(1,941)	(444)

NET LEVERAGE RATIO (NET DEBT/EBITDA)¹

1 EBITDA: including acquisitions & divestitures with a purchase price above €50m and excluding (gain) loss related to divestitures of Care Coordination activities and excluding NxStage related transaction costs │ 2 Incl. IFRS 16 │ 3 Excl. IFRS 16 │ 4 Latest update: S&P: Jan. 8, 2019; Moody's: May 15, 2018; Fitch: March 8, 2018

OUTLOOK¹

(cc)	TARGETS 2019	2018 BASE (in € million)
Revenue growth adjusted	3 to 7%	16,026
Net income growth adjusted	(2) to 2%	1,341

(cc)	TARGETS 2020
Revenue growth adjusted	Mid to high single digit growth rate
Net income growth adjusted	Mid to high single digit growth rate

1 Targets for 2019 and 2020 are in constant currency. These targets as well as the 2018 base are and will be adjusted in order to make the business performance in the respective periods comparable for items such as: FCPA related charges, the IFRS 16 implementation, the contributions from Sound in H1 2018, the gain (loss) related to divestitures of Care Coordination activities and expenses for the cost optimization program. All effects from the NxStage acquisition are excluded from the targets for 2019 and 2020.

Q1 2019: PROFIT AND LOSS1

	Q1 2019 € million	Q1 2018 € million	Growth in %	Growth in %cc
Revenue	4,133	3,976	4	(1)
Revenue adjusted	4,125	3,725	11	6
EBIT	537	497	8	3
EBIT margin in %	13.0	12.5	(0.5)pp	(0.5)pp
EBIT adjusted	551	506	9	4
EBIT adjusted margin in %	13.4	13.6	(0.2)pp	(0.2)pp
Net interest expense	108	83	30	24
Income before taxes	429	414	4	(1)
Income tax expense	101	84	20	15
Tax rate in %	23.5	20.3	3.2	3.4
Non-controlling interest	57	51	11	3
Net income	271	279	(3)	(6)
Net income adjusted	318	296	8	3

1 For a detailed reconciliation please refer to chart 27

Q1 2019: REVENUE AND NET INCOME GROWTH

REVENUE ADJUSTED, € MILLION – TARGET: 3–7%CC GROWTH

NET INCOME ADJUSTED, € MILLION – TARGET: (2)–2%CC GROWTH

© │ June 2019

Q1 2019: RECONCILIATION ADJUSTMENTS

RECONCILIATION OF NON-IFRS FINANCIAL MEASURES TO THE MOST DIRECTLY COMPARABLE IFRS FINANCIAL MEASURES

	Q1 2019 € million	Q1 2018 € million
Revenue	4,133	3,976
IFRS 16 Implementation	22
NxStage operations	(30)
Sound Q1 20181		(251)
Revenue adjusted	4,125	3,725
Net income2	271	279
IFRS 16 Implementation	18
NxStage operations	14
NxStage costs	12
Cost Optimization costs	3
Sound Q1 20181		4
(Gain) loss related to divestitures of Care Coordination activities		13
Net income2 adjusted	318	296

1 Contribution of Sound Physicians │ 2 Attributable to shareholders of FMC AG & Co. KGaA

Q1 2019: REGIONAL MARGIN PROFILE

NORTH AMERICA (60% OF EBIT¹)

DIALYSIS BUSINESS MARGIN OF 12.9%

• Negative: Higher personnel expense, integration and operational costs associated with NxStage, unfavorable impact from legal settlements
• Positive: Contributions from income attributable to a consent agreement on certain pharmaceuticals, favorable effects from the IFRS 16 implementation and from manufacturing
• U.S. revenue per treatment \$355 (Q1 2018: \$348) U.S. cost per treatment \$301² (Q1 2018: \$289)

CARE COORDINATION MARGIN OF 13.0%

▪ Positive: Prior year loss related to divestiture of Care Coordination activities, increased member months for health plan services, increased volumes for vascular services, a positive IFRS 16 implementation effect

Q1 2019: REGIONAL MARGIN PROFILE

EMEA (22% of EBIT1)	Operating income margin development reflects Positive: Reduction of a contingent consideration ▪ liability related to Xenios ▪ Negative: Higher bad debt expense, higher rent expense, impact from one less dialysis day	109 17.1% 17.1% Q1 2018	138 21.1% 21.1% Q1 2019
ASIA-PACIFIC (16% of EBIT1)	Operating income margin development impacted by ▪ Positive: Favorable foreign currency transaction effects, a favorable impact from business growth Care Coordination margin of 11.3%	74 19.0% Q1 2018	95 22.1% Q1 2019
LATIN AMERICA (2% of EBIT1)	Operating income margin development reflects ▪ Negative: Hyperinflation impact in Argentina ▪ Positive: Favorable foreign currency transaction effects	14 8.3% 10.2% Q1 2018	11 7.1% Q1 2019

EBIT in € million; % EBIT-margin

Diagrams: different scales applied │ 1 Excl. Corporate

RECONCILIATION OF NON-IFRS FINANCIAL MEASURES TO THE MOST DIRECTLY COMPARABLE IFRS FINANCIAL MEASURES

€ million	Q1 2019 excl. IFRS 16	Q1 2019	2018	2017
Debt
Short term debt	1,320	1,320	1,205	760
+ Short term debt from related parties	107	107	189	9
+ Current portion of long-term debt	1,516	1,512	1,107	884
+ Current portion of long-term lease liabilities	-	615	-	-
+ Current portion of long-term lease liabilities from related parties	-	16	-	-
+ Long-term debt, less current portion	5,690	5,681	5,045	5,795
+ Long-term lease liabilities, less current portion	-	3,864	-	-
+ Long-term lease liabilities from related parties, less current portion	-	117	-	-
Total debt	8,633	13,232	7,546	7,448
Cash and cash equivalents	959	959	2,146	978
Total net debt	7,674	12.273	5,400	6,470

EBITDA

RECONCILIATION OF NON-IFRS FINANCIAL MEASURES TO THE MOST DIRECTLY COMPARABLE IFRS FINANCIAL MEASURES

€ million	Q1 2019 excl. IFRS 16	Q1 2019	2018	2017
EBITDA1
Last twelve month operating income (EBIT)	2,244	2,898	2,215	2,372
+ Last twelve month depreciation and amortization	770	937	716	731
+ Non-cash charges	45	45	45	51
EBITDA (annualized)	3,059	3,880	2,976	3,154
Net leverage ratio (Net debt/EBITDA)	2.5	3.2	1.8	2.1

1 EBITDA: including acquisitions & divestitures with a purchase price above €50m and excluding (gain) loss related to divestitures of Care Coordination activities and excluding NxStage related transaction costs

ACQUISITIONS & INVESTMENTS AND CAPITAL EXPENDITURES

RECONCILIATION OF NON-IFRS FINANCIAL MEASURES TO THE MOST DIRECTLY COMPARABLE IFRS FINANCIAL MEASURES

€ million	Q1 2019	Q1 2018
Acquisitions and investments
Acquisitions, investments and net purchases of intangible assets	(1,829)	(181)
- Proceeds from divestitures	11	-
= Acquisitions and investments, net of divestitures	(1,818)	(181)
Thereof investments in securities, net of divestitures	4	(146)

	Q1 2019	Q1 2018
Capital expenditures, net
Purchase of property, plant and equipment	(201)	(221)
- Proceeds from sale of property, plant & equipment	2	3
= Capital expenditure, net	(199)	(218)

Q1 2019: EFFECTS ACCORDING TO IFRS 16

EFFECTS INCLUDING NXSTAGE

Balance Sheet	Q1 2019 € million
Assets	4,228
Right-of-use assets	4,311
Machinery and equipment	(26)
Other assets	(57)
Liabilities	4,228
Lease Liablities	4,612
Other financial debt	(12)
Other liablities	(218)
Equity	(154)

Profit and loss statement	Q1 2019 € million
Revenue	(22)
Profit from sale-leaseback transactions	(12)
Rental expenses	(196)
EBITDA	184
Depreciation expense	(167)
EBIT	17
Net interest expenses	42
Taxes	(7)
Net Income	(18)

Cash flow statement	Q1 2019 € million
Cash provided by operating activities	142
Cash used in investing activities	(10)
Cash used in financing activities	(132)
Total	0

• Net leverage ratio increased by 0.7.

ESTIMATED EFFECTS ACCORDING TO IFRS 16

ESTIMATED EFFECTS EXCLUDING NXSTAGE

Balance Sheet	Impact 2019e € million
Assets
Right-of-use assets	~3,950
Machinery and equipment	~30
Other assets	~(20)
Liabilities
Lease Liablities	~4,280
Other financial debt	~70
Other liablities	~(190)
Equity	~(200)

Profit and loss statement	Impact 2019e € million
Revenue	~(110)
Profit from sale-leaseback transactions	~(30)
Rental expenses	~(790)
EBITDA	~760
Depreciation expense	~(680)
EBIT	~80
Net interest expenses	~170
Taxes	~(20)
Net Income	~(70)

Cash flow statement	Impact 2019e € million
Cash provided by operating activities	~580
Cash used in investing activities	~(80)
Cash used in financing activities	~(500)
Total	0

• Net leverage ratio will increase by about 0.6.

NXSTAGE: EXCLUDED FROM THE TARGETS 2019 AND 2020

EFFECTS FROM THE NXSTAGE ACQUISITION

• All effects from the NxStage acquisition are excluded from the company's communicated targets 2019 and 2020.
• Total integration costs of around EUR 50 to EUR 75 million over the three years following the closing of the transaction (not reflected in table below).
• Full year effect of incremental intangible assets amortization to be in the range of EUR 70 to 80 million for the first two years, then drop to EUR 45 to 55 million thereafter (reflected in table below).

Estimated effects of the NxStage acquisition excluding integration costs:

EUR million1	2019	2020
Revenue	240 to 260	310 to 330
Operating income (EBIT)	(30) to (20)	20 to 30
Interest	(75) to (65)	(85) to (75)
Net income	(75) to (65)	(40) to (30)

1 The numbers are excluding effects from the implementation of IFRS 16 and excluding integration costs. 2019 estimates cover the period starting on February 21, 2019 (closing date) until year-end 2019.

2018: PROFIT AND LOSS¹

	2018 € million	2017 € million	Growth in %	Growth in %cc
Revenue	16,547	17,784	(7)	(2)
Revenue on a comparable basis	16,547	16,739	(1)	4
Revenue adjusted	16,547	16,645	(1)	4
EBIT	3,038	2,362	29	33
EBIT margin in %	18.4	13.3	5.1pp	4.8pp
EBIT on a comparable basis	2,346	2,278	3	6
EBIT adjusted	2,346	2,409	(3)	1
EBIT adjusted margin in %	14.2	14.5	(0.3)pp	(0.6)pp
Net interest expense	301	365	(17)	(14)
Income before taxes	2,737	1,997	37	42
Income tax expense	511	443	15	21
Tax rate in %	18.7	22.2	(3.5)pp	(3.3)pp
Non-controlling interest	244	274	(11)	(7)
Net income	1,982	1,280	55	60
Net income on a comparable basis	1,377	1,242	11	14
Net income adjusted	1,185	1,162	2	4

1 For a detailed reconciliation please refer to chart 37

2018: RECONCILIATION ADJUSTMENTS

RECONCILIATION OF NON-IFRS FINANCIAL MEASURES TO THE MOST DIRECTLY COMPARABLE IFRS FINANCIAL MEASURES

	2018 € million	2017 € million
Revenue	16,547	17,784
IFRS 15 Implementation		(486)
Sound H2 20171		(559)
Revenue on a comparable basis	16,547	16,739
VA Agreement2		(94)
Revenue adjusted	16,547	16,645
Net income5	1,982	1,280
(Gain) loss related to divestitures of Care Coordination activities	(673)
Sound H2 20171		(38)
2018 FCPA Related Charge	28
U.S. Ballot Initiatives3	40
Net income5 on a comparable basis	1,377	1,242
VA Agreement2		(51)
Natural Disaster Costs4		11
2017 FCPA Related Charge		200
U.S. Tax Reform (excl. Sound H2 2017)6	(192)	(240)
Net income5 adjusted	1,185	1,162

1 Sound H2 2017: contribution of Sound Physicians │ 2 VA Agreement: Agreement with the United States Departments of Veterans Affairs and Justice │ 3 U.S. Ballot Initiatives: contributions to the opposition to the ballot initiatives in the U.S. │ 4 Natural Disaster Costs: three hurricanes and an earthquake │ 5 Attributable to shareholders of FMC AG & Co. KGaA │ 6 U.S. Tax Reform: impacts from U.S. tax reform

2018 BASE FOR TARGETS 2019 ON A QUARTERLY BASIS

EUR million	FY 2018	Q1 2018	Q2 2018	Q3 2018	Q4 2018
Revenue	16,547	3,976	4,214	4,058	4,300
Sound H1 20181	(521)	(251)	(258)	(7)	(5)
Revenue adjusted	16,026	3,725	3,956	4,051	4,295
EBIT	3,038	497	1,401	527	613
Sound H1 20181	(14)	(4)	(10)	0	0
(Gain) loss related to div. of Care Co.	(809)	13	(833)	(10)	21
2018 FCPA related charge	77	0	0	75	2
EBIT adjusted	2,292	506	558	592	636
Net income2	1,982	279	994	285	425
Sound H1 20181	4	4	0	0	0
(Gain) loss related to div. of Care Co.	(673)	13	(686)	(17)	17
2018 FCPA related charge	28	0	0	75	(47)
Net income2 adjusted	1,341	296	308	343	395

1 Contribution of Sound Physicians │ 2 Attributable to shareholders of FMC AG & Co. KGaA

RETURN ON INVESTED CAPITAL¹ (ROIC)

▪ Long-term value creation based on accretive acquisitions and organic growth

▪ ROIC adjusted² (esp. for divestitures of Care Coordination activities): around 8.0%

1 Based on net operating profit after tax & average invested capital; adjusted for largest acquisitions and divestitures │

2 Adjusted for the divestiture of Care Coordination activities, FCPA related charge, U.S. Ballot Initiatives, U.S. tax reform / including these effects, ROIC for FY 2018 was 12.4%

Q1 2019: QUALITY OUTCOMES REMAIN ON HIGH LEVEL1

	NORTH AMERICA		EMEA		LATIN AMERICA		ASIA-PACIFIC
% of patients	Q1 2019	Q1 2018	Q1 2019	Q1 2018	Q1 2019	Q1 2018	Q1 2019	Q1 2018
Kt/V ≥ 1.2	97	97	94	95	90	92	95	96
Hemoglobin = 10–12 g/dl	70	71	82	83	49	52	56	57
Calcium = 8.4–10.2 mg/dl	85	85	79	80	77	78	74	74
Albumin ≥ 3.5 g/dl	81	80	89	88	91	90	90	89
Phosphate ≤ 5.5 mg/dl	60	62	80	81	76	76	66	68
Patients without catheter (after 90 days)	83	83	79	80	80	80	85	87
in days
Days in hospital per patient year	10.3	11.0	7.5	7.8	4.3	4.0	3.0	3.6

1 Definitions of quality parameters cf. 2018 Annual Report, Section "Non-Financial Group Report" page 87

SUSTAINABILITY GOVERNANCE STRUCTURE

GLOBAL SUSTAINABILITY GOVERNANCE

• At Fresenius Medical Care, sustainability is firmly established at Board level.
• Responsibility for the Company's sustainability efforts lies with the Sustainability Decision Board (headed by the CEO).
• The Sustainability Decision Board and the Corporate Sustainability Committee enable the Corporate Sustainability Office to manage Fresenius Medical Care's sustainability program.
• The Corporate Sustainability Committee has an advisory and steering role. It consists of senior representatives of all regions and global functions.

EXCHANGE RATES U.S. DIALYSIS DAYS PER QUARTER

Euro vs.		Q1 2019	Q1 2018	FY 2018
€:\$	Period end	1.124	1.232	1.145
	Average	1.136	1.229	1.181
€:CNY	Period end	7.540	7.747	7.875
	Average	7.663	7.815	7.808
€:RUB	Period end	72.856	70.890	79.715
	Average	74.909	69.865	74.026
€:ARS	Period end	48.692	24.782	43.039
	Average	44.290	24.219	32.984
€:BRL	Period end	4.387	4.094	4.444
	Average	4.278	3.989	4.308

	Q1	Q2	Q3	Q4	Full year
2019	76	78	79	80	313
2018	77	78	78	80	313
2017	77	78	79	79	313
2016	78	78	79	79	314
2015	76	78	79	79	312

DEFINITIONS

cc	Constant currency
HD	Hemodialysis
PD	Peritoneal dialysis
Net income	Net income attributable to shareholders of FME
Sound Q1 2018	Contribution of Sound Physicians on the profit and loss statement in the first quarter 2018

REPORTING DATES & AGM

July 30	Report on 2nd quarter 2019
October 29	Report on 3rd quarter 2019

CONFERENCES & MEET THE MANAGEMENT

June 5 & 6	dbAccess Berlin Conference, Berlin
June 12	Goldman Sachs Global Healthcare Conference, Rancho Palos Verdes
June 18 & 19	SocGen "European Angle Conference", Tokyo
June 20	JP Morgan European Healthcare Conference, London
June 27	Site Visit St. Wendel, Meet the Management

¹ Please note that dates and/or participation might be subject to change

FME INVESTOR RELATIONS

Else-Kröner-Str. 1 61352 Bad Homburg v.d.H. Germany

TICKER: FME or FMS (NYSE) WKN: 578 580 ISIN: DE00057858002

DR DOMINIK HEGER

Head of Investor Relations and Corporate Communications

+49(0) 6172–609-2601 dominik.heger@fmc-ag.com

ROBERT ADOLPH

Senior Director Investor Relations

+49(0) 6172–609-2477 robert.adolph@fmc-ag.com

PHILIPP GEBHARDT

Senior Manager Investor Relations

+1-781-699-2142 philipp.gebhardt@fmc-ag.com